Inclusion Criteria:  females or males >18 years old at the time of informed consent signature; diagnosis of potentially resectable or de novo metastatic (stage II-IV) invasive carcinoma of the breast; eligible for standard neoadjuvant or palliative paclitaxel and/or carboplatin-based chemotherapy as determined by Investigator;  triple negative tumor defined as:  hormone receptor-negative (<1% ER/PgR expression); HER2-negative (Immunohistochemistry (IHC) score ≤1 or IHC score =2 and negative for the amplification by in situ hybridization); multicentric/multifocal disease is allowed, provided that all lesions have been biopsied and their phenotype has been confirmed pathologically as TNBC; no previous anticancer therapy for this malignancy; clinically or radiographically measurable disease (discrete lesion only, enhancement is not included) within the breast, that can be biopsied, defined as longest diameter >2 cm; multicentric or multifocal disease is allowed if at least 1 lesion is >2 cm; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1; adequate bone marrow and organ function as defined by the following local laboratory values: hemoglobin ≥9 g/dL; absolute neutrophil count (ANC) ≥1500/μL; platelets ≥100,000/μL; total bilirubin ≤ institutional upper limit of normal (ULN), unless diagnosis of Gilbert syndrome; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x ULN; creatinine ≤ ULN OR creatinine clearance ≥50 mL/min per Cockcroft-Gault equation for patients with creatinine levels greater than ULN. blood glucose level <120 mg/dL after at least 6 hours of fasting; standard 12-lead electrocardiogram (ECG) without clinically significant abnormalities; ability to undergo contrast-enhanced MRI; ability to swallow and retain oral medication; all study participants of child-bearing potential must agree to use adequate contraceptive methods prior to study entry, during the study and for the following 3 weeks (females) or 14 weeks (males); prior chemotherapy, other targeted anticancer therapies, or prior radiation therapy (outside of treated breast) for other malignancy treated with radical intent is allowed, provided the treatment was completed ≥1 year before informed consent signature; prior bisphosphonate therapy is allowed; willing and able to undergo all the procedures required by the study protocol; provision of written informed consent form prior to receiving any study related procedure.  Exclusion Criteria:  inflammatory breast cancer; prior systemic treatment for this malignancy; prior treatment with CDK4/6 inhibitor; known hypersensitivity to study medications or any of their excipients; major surgery or radiotherapy (apart from limited field radiotherapy for symptom control) within 14 days prior to randomization; concurrent invasive malignancy; known HIV, active HBV or HCV infection; active autoimmune disease requiring ongoing immunosuppressive therapy; history of allotransplantation; concurrent treatment with systemic immunosuppressive agents, including steroids, within 3 weeks of enrolment; presence of implants or devices not compatible with MRI; pregnant or nursing female participants; receiving strong inhibitors or inducers of CYP3A4/5 or medications with narrow therapeutic window that are predominantly metabolized through CYP3A4/5; impairment of GI function that may significantly alter the absorption of the oral trial treatments; unwilling or unable to follow protocol requirements, including obligatory biopsies; any condition which in the Investigator's opinion deems the participant an unsuitable candidate to receive study drugs; any other concurrent severe and/or uncontrolled medical condition that would, in the Investigator's judgment, contraindicate patient participation in the clinical trial or compromise compliance with the protocol.